News

The proposed DRUG Act will spur innovation in biotech, and reduce costs

As the vibrant biotechnology and life sciences industry in Virginia flourishes, our mission at the Virginia Biotechnology Association remains steadfast: to promote innovation and growth through strengthened advocacy, talent attraction, development and retention while advancing the next generation of leaders.

We succeed because Virginia encourages risk-takers to develop new health care and technology treatments.

Virginia’s biotechnology sector contributes more than $8 billion to our economy. Yet, we could do more. We have seen Pharmacy Benefit Managers (PBMs) pursue opaque and often anti-competitive practices that impede additional investment into the biopharmaceutical sector.

We urge those in Washington to reform PBM practices, supporting legislation like the Delinking Revenue from Unfair Gouging (DRUG) Act, introduced by Virginia Congresswoman Abigail Spanberger. This reform protects the interests of all Virginians and the innovative spirit that defines our industry.

The DRUG Act realigns PBMs’ incentives that favor higher-priced medicines. Congress can reform a system so it supports innovation while lowering the cost of prescription drugs for patients.

PBM reform, like the DRUG Act, spurs competition, making the market work as it should — by basing PBM fees on the services they provide rather than the price of medicines. We shouldn’t reward behaviors that place profits over patients.

The positive ripple effects of DRUG Act-inspired PBM reform would extend beyond the biotech sector, generating savings for employers and plan sponsors. By incentivizing cost-effective medications, Virginians will have access to more cost-effective treatments for patients, employers and plan sponsors. Most importantly, patients will benefit from expanded coverage of less expensive medicines.

Congresswoman Spanberger should be applauded for introducing the bipartisan DRUG Act to support real reform of PBMs to help lower prescription drug costs.

The Virginia Biotechnology Association is committed to championing our innovators by supporting policies that create a healthier and more prosperous future. We urge our delegation to support this critical reform.

Recent News

07/23/2026

Activation Capital Expands the Bio+Tech Center, Doubling Laboratory Capacity to Strengthen Virginia’s Life Sciences Entrepreneurship and Innovation Ecosystem

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced an expansion of its Bio+Tech Center to support the continued growth of life sciences entrepreneurship across the region. Activation Capital’s Bio+Tech Center is a life sciences incubator located within the Virginia Bio+Technology Research Park. Serving as both a physical and programmatic

07/22/2026

Epidarex Announces Leadership Appointments

With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen our impact across the US and UK life science ecosystems, recognizing and elevating exceptional talent within our team is a vital part of that journey. These transitions reflect our continued

07/22/2026

Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer

Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO), dedicated to strengthening the nation’s pharmaceutical supply chain and protecting America’s medicine cabinet, today announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer. Venkatraman brings more than 25 years of experience in pharmaceutical development, process chemistry, manufacturing, and scientific leadership. He